CCNL2 (cyclin L2) is a regulatory component of the cyclin-L-CDK11 complex that controls transcription and pre-mRNA splicing processes 1. The protein functions as a cell cycle regulator with dual roles in proliferation and apoptosis. In cancer contexts, CCNL2 demonstrates oncogenic properties by promoting tumor growth and chemotherapy resistance. In ovarian cancer, elevated CCNL2 expression correlates with poor prognosis and enhanced cisplatin resistance, with its expression regulated by YBX1 through 5-methylcytosine modification 2. Similarly, the CDK11/CCNL2 complex promotes paclitaxel resistance in cervical cancer by phosphorylating NF2 and inactivating the Hippo signaling pathway 3. CCNL2 also participates in alternative splicing regulation, where aberrant exon skipping events involving CCNL2 contribute to pancreatic cancer progression 1. Beyond cancer, CCNL2 serves as a mechanosensitive gene in mesenchymal stem cells, responding to mechanical stress with altered expression patterns 4. In inflammatory conditions like rheumatoid arthritis, CCNL2 influences T-cell cycle regulation and is targeted by the long non-coding RNA lnc-RNU12 5. The protein's expression can be therapeutically modulated, as demonstrated by small molecule inhibitors that enhance chemotherapy sensitivity in cancer models.